Chen Liling, Huang Zhidong, Zhao Xiaoli, Liang Jingjing, Lu Xiaozhao, He Yibo, Kang Yu, Xie Yun, Liu Jin, Liu Yong, Yang Jin, Yu Weixu, Deng Wanling, Pan Yuxiong, Lu Jin, Yang Yanfang, Xie Xujing, Qian Xiaoxian, Xu Qingbo, Chen Longtian, Chen Kaihong, Chen Shiqun
Department of Cardiology, Longyan First Hospital Affiliated of Fujian Medical University, Longyan, China.
Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Front Cardiovasc Med. 2022 Feb 24;9:820178. doi: 10.3389/fcvm.2022.820178. eCollection 2022.
Definitions of declined left ventricular ejection fraction (LVEF) vary across studies and research results concerning the association of mortality with declined LVEF are inconsistent. Thus, this study aimed to assess the impact of early worsening LVEF on mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF) and to establish independent predictors of early worsening LVEF.
A total of 1,418 consecutive patients with HFpEF with LVEF remeasurement from the Cardiorenal Improvement registry were included in this study. Worsening LVEF was defined as an absolute decline ≥ 5% from baseline LVEF within 3 to 12 months after discharge. The Cox and logistic regression analyses were performed to assess prognostic effects and predictors for worsening LVEF, respectively. Among 1,418 patients with HFpEF, 457 (32.2%) patients exhibited worsening LVEF. During a median follow-up of 3.2 years (interquartile range: 2.3-4.0 years), 92 (6.5%) patients died. Patients with HFpEF with worsening LVEF had higher mortality relative to those with nonworsening LVEF [9.2 vs. 5.2%; adjusted hazard ratio (aHR): 2.18, 95% CI: 1.35-3.52]. In the multivariate binary logistic regression analysis, baseline left ventricular end-diastolic dimension (LVEDD), LVEF, high-density lipoprotein cholesterol (HDL-C), atrial fibrillation (AF), and diabetes mellitus (DM) emerged as predictive factors of worsening LVEF.
This study demonstrated that about one out of three patients with HFpEF experiences worsening LVEF during follow-up, which is associated with 2.2-fold increased mortality. Increased LVEDD and LVEF, low HDL-C levels, AF, and DM were predictors of worsening LVEF. Further studies are needed to prospectively assess the efficacy of early active management on prognosis in patients with HF with worsening LVEF.
ClinicalTrials.gov, identifier NCT04407936.
左心室射血分数(LVEF)下降的定义在不同研究中有所不同,并且关于LVEF下降与死亡率之间关联的研究结果并不一致。因此,本研究旨在评估早期LVEF恶化对射血分数保留的心力衰竭(HFpEF)患者死亡率的影响,并确定早期LVEF恶化的独立预测因素。
本研究纳入了共1418例来自心肾改善登记处且重新测量了LVEF的连续性HFpEF患者。LVEF恶化定义为出院后3至12个月内LVEF较基线LVEF绝对下降≥5%。分别进行Cox回归分析和逻辑回归分析以评估LVEF恶化的预后影响和预测因素。在1418例HFpEF患者中,457例(32.2%)患者出现LVEF恶化。在中位随访3.2年(四分位间距:2.3 - 4.0年)期间,92例(6.5%)患者死亡。LVEF恶化的HFpEF患者相对于LVEF未恶化的患者具有更高的死亡率[9.2%对5.2%;调整后风险比(aHR):2.18,95%置信区间:1.35 - 3.52]。在多变量二元逻辑回归分析中,基线左心室舒张末期内径(LVEDD)、LVEF、高密度脂蛋白胆固醇(HDL-C)、心房颤动(AF)和糖尿病(DM)成为LVEF恶化的预测因素。
本研究表明,约三分之一的HFpEF患者在随访期间出现LVEF恶化,这与死亡率增加2.2倍相关。LVEDD增加、LVEF升高、HDL-C水平降低、AF和DM是LVEF恶化的预测因素。需要进一步的研究来前瞻性评估早期积极管理对LVEF恶化的HF患者预后的疗效。
ClinicalTrials.gov,标识符NCT04407936。